Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $131K invested in Phio Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6.8% less ownership
Funds ownership: 8.9% → 2.11% (-6.8%)
53% less capital invested
Capital invested by funds: $277K → $131K (-$147K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$76.8K |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$47.1K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$19.9K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$1.67K |
| 5 |
AssetMark Inc
Concord,
California
|
+$203 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$80.1K |
| 2 |
HF
HRT Financial
New York
|
-$76K |
| 3 |
VF
Virtu Financial
New York
|
-$74K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.24K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.03K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $54.1K | +$76.8K | +41,586 | New |
|
|
2
Cetera Investment Advisers
Schaumburg,
Illinois
| $50K | +$47.1K | +25,500 | +196% |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $14K | +$19.9K | +10,800 | New |
|
4
Morgan Stanley
New York
| $7.8K | +$164 | +89 | +2% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3.25K | -$4.03K | -2,181 | -47% |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $1.26K | +$1.67K | +905 | +1,437% |
|
|
7
AssetMark Inc
Concord,
California
| $143 | +$203 | +110 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $134 | -$4.24K | -2,294 | -96% |
|
9
Bank of America
Charlotte,
North Carolina
| $53 | +$63 | +34 | +486% |
|
|
AWM
10
Activest Wealth Management
Aventure,
Florida
| $12 | – | – | – |
|
11
Barclays
London,
United Kingdom
| $7 | -$366 | -198 | -98% |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$80.1K | -44,526 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$76K | -42,338 | Closed |
|
|
VF
14
Virtu Financial
New York
| – | -$74K | -40,910 | Closed |
|
PHIO Hedge Fund Activity: Q1 2025 in Review
11 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2025, worth a combined $131K — down 53% from $277K a quarter earlier.
Fund positioning in PHIO was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $76.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $80.1K sold.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $131K of Phio Pharmaceuticals stock for Q1 2025, down 53% quarter-over-quarter.
- 3 funds opened new Phio Pharmaceuticals positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q1 2025 was Geode Capital Management, an estimated $76.8K added.
- The largest Phio Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $80.1K sold.
Based on aggregated 13F filings for Q1 2025.